HOME >> MEDICINE >> NEWS
New agreement questions NHS relation with industry

The Department of Health's new clinical trials agreement raises questions about the NHS's relation with the drug industry, says an editorial published on bmj.com today.

Following the tragedy of the TGN1412 trial, the Department of Health announced last month that a model clinical trials agreement has been finalised. This provides a template that can be used by all NHS trusts for any clinical trial, without modification.

But before embracing this agreement with open arms, we should examine what it actually says and what the deeper implications might be, warns Professor Michael Goodyear of Dalhousie University, Canada.

The agreement is the product of a unique consortium of industry, government, and academia, but other organisations, such as the Central Office for Research Ethics Committees, are not mentioned, despite being central to many issues covered in the agreement.

The agreement also applies only to contract research (commercial, industry sponsored trials usually directed towards pharmaceutical product licensing). It does not apply to phase I testing with healthy volunteers (as in TGN1412), to studies initiated by investigators, to trials in which the sponsor merely provides funding, or to research in non-NHS institutions.

While collaboration is admirable, we must realise that the development of a business model for research is a primary motivation behind this initiative, says Goodyear. As the guidance document states, the NHS is being "harnessed" in what is essentially a competitive model.

A surprising and disturbing element of the agreement relates to the crucial principles of transparency and accountability in research. Rather than incorporating and upholding the new and widely supported standards for an open research culture, the agreement has embedded an older and more problematic industry standard.

And, given that this agreement appears at a time when public trust in the drug industry
'"/>

Contact: Emma Dickinson
edickinson@bmj.com
44-020-738-36529
BMJ-British Medical Journal
16-Nov-2006


Page: 1 2

Related medicine news :

1. Heading to Siberia: UH signs agreement with Russian Academy of Sciences
2. Research agreement to advance new imaging technology
3. Access to science enhanced by new NIH-ASH agreement
4. Patent laws and US trade agreements are hindering access to HIV treatment
5. Stevens in agreement with Competitive Technologies to commercialize Stevens IP worldwide
6. GE Healthcare and St. Josephs Hospital and Medical Center, Phoenix announce research agreement
7. New licensing agreement to maximize AIDS drug development
8. AstraZeneca and M. D. Anderson Cancer Center form umbrella scientific collaboration agreements
9. Microbicide field praises agreement to license new AIDS drugs
10. Implementing European Space Policy: Key ESA/EC agreement on Earth Observation data signed today
11. Proteome Systems signs agreement with Prince Henrys Institute for Ovarian Cancer Diagnostic Test

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/31/2016)... ... , ... The Global Wellness Summit (GWS), an annual conference for ... wellness, travel, spa and beauty in Europe. The organization asked its partner experts in ... and researchers - to forecast where wellness is headed in Europe. Predictions range from ...
(Date:5/31/2016)... ... May 31, 2016 , ... Interest is on the ... tool and as an orthogonal tool for RNAi hit validation. A key reason may ... guide RNAs—allows rapid generation of CRISPR RNA (crRNA) collections in arrayed formats. , ...
(Date:5/31/2016)... ... , ... Dr. Charles A. Ditta attained his Doctor of Medical Dentistry Degree ... 1986, where he graduated in the top ten percentile of his class. Dr. Ditta ... He has been a member in good standing for thirty years in the American ...
(Date:5/30/2016)... ... May 30, 2016 , ... As the CDC relaxes its stance on traditional ... to keep their households lice free. , According to a May 26 article ... keep kids in the classroom despite the fact that they may be harboring an ...
(Date:5/29/2016)... ... ... Whole Health Supply is happy to announce the favorable reception of its ... new style of nail clipper has a wider jaw opening that is useful for ... actual handle is 2.5mm thick to accommodate the cutting force. This is the maximum ...
Breaking Medicine News(10 mins):
(Date:5/30/2016)... , May 30, 2016 ... H1 2016" market research report with comprehensive information ... with comparative analysis at various stages, therapeutics assessment ... of administration (RoA) and molecule type, along with ... It also reviews key players involved in the ...
(Date:5/27/2016)... 2016 Hutchison China MediTech ... on the highly lucrative global oncology and immunology ... potential first-in-class or best-in-class tyrosine kinase inhibitor (TKI) ... strategic partners. HCM,s profitable Chinese healthcare business continues ... expect progress of the mid-to-late-stage pipeline during 2016-17 ...
(Date:5/26/2016)... 2016 A key trend that ... emergence of new treatments. Cardax, a development stage life ... The therapy is expected to fulfil large unmet medical ... conducting studies to develop new treatments for osteoarthritis. One ... involved in osteoarthritis are being investigated, and early trials ...
Breaking Medicine Technology:
Cached News: